Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
December 07, 2018 09:15 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and...
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
December 06, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and...
GBT Announces New Employment Inducement Grants
December 04, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 30, 2018, the compensation...
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
December 03, 2018 10:00 ET
|
Global Blood Therapeutics, Inc.
Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable...
GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
December 03, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
Pre-NDA Meeting to be Requested for First Quarter of 2019 Company to Host Conference Call and Webcast Today, Monday, December 3, at 5:30 a.m. PT/8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 03,...
GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor
December 02, 2018 19:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the company will host a conference call to...
GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results
November 06, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the third quarter ended...
GBT Announces New Employment Inducement Grants
November 06, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation...
GBT Announces Upcoming Data Presentations at 60th American Society of Hematology (ASH) Annual Meeting & Exposition
November 01, 2018 09:00 ET
|
Global Blood Therapeutics, Inc.
Company to Present Three Oral Presentations, Including Results Beyond 12 Weeks from Part A of the HOPE Study Company to Host Investor Webcast on Monday, December 3 SOUTH SAN FRANCISCO, Calif., Nov. ...
GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America (SCDAA) Convention
October 04, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that three abstracts related to its sickle cell disease (SCD)...